Ping Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ping Chen has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Guoxin Zhang
The First School of Clinical Medicine Ningxia Medical University Yinchuan Ningxia China
1 shared publicationQingxia Zhou
Oncology Department Wuzhong People's Hospital Wuzhong Ningxia China
1 shared publication- Tingting Wei
Department of Medical Oncology General Hospital of Ningxia Medical University Yinchuan Ningxia China
1 shared publication Tong She
Oncology Department Hospital of Zhongwei Zhongwei Ningxia China
1 shared publicationXinlan Liu
Department of Medical Oncology Ningxia Hui Autonomous Region Hospital Yinchuan Ningxia China
1 shared publication- Xue Cao
The First School of Clinical Medicine Ningxia Medical University Yinchuan Ningxia China
1 shared publication
Latest Publications
- 17 July 2025
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 39 (8) , e70398
D‐Mannose Upregulates Testin via the NF‐κB Pathway to Inhibit Breast Cancer Proliferation
D ‐Mannose is a naturally occurring monosaccharide known to enhance the effects of chemotherapy, immunotherapy, and radiotherapy in cancer patients. This study aimed to investigate the growth‐regulating mechanism of d ‐mannose on breast cancer (BC) cells. d ‐mannose was treated on MDA‐MB‐231 and MCF‐7 BC cells. Cell counting kit‐8 (CCK‐8), wound healing test, transwell invasion, and flow cytometry assays were used to assess the viability, invasion, migration, and apoptosis of d ‐mannose treated BC cells. Testin (TES) expressions in d ‐mannose treated BC cells were evaluated using western blot analysis, qRT‐PCR, and immunofluorescence assays. The potential regulatory relationship between d ‐mannose and TES in BC cells were explored by analyzing TES gene expression profile in BC cells using the University of California Santa Cruz (UCSC) Xena browser database. Immunohistochemical analysis of TES protein was performed in BC tissue samples obtained from patients. It was found that d ‐mannose significantly inhibited the growth of MDA‐MB‐231 and MCF‐7 cells in a concentration and time‐dependent manner by activating the NF‐κB signaling pathway and upregulating TES expression. TES knockdown downregulated the NF‐κB1, NF‐κB2, and p65 protein expressions. Therefore, this study highlights that d ‐mannose have the potential to promote anticancer effects upon further trials using in vivo models and clinical studies.
- 17 July 2025
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 39 (8) , e70398
D‐Mannose Upregulates Testin via the NF‐κB Pathway to Inhibit Breast Cancer Proliferation
D ‐Mannose is a naturally occurring monosaccharide known to enhance the effects of chemotherapy, immunotherapy, and radiotherapy in cancer patients. This study aimed to investigate the growth‐regulating mechanism of d ‐mannose on breast cancer (BC) cells. d ‐mannose was treated on MDA‐MB‐231 and MCF‐7 BC cells. Cell counting kit‐8 (CCK‐8), wound healing test, transwell invasion, and flow cytometry assays were used to assess the viability, invasion, migration, and apoptosis of d ‐mannose treated BC cells. Testin (TES) expressions in d ‐mannose treated BC cells were evaluated using western blot analysis, qRT‐PCR, and immunofluorescence assays. The potential regulatory relationship between d ‐mannose and TES in BC cells were explored by analyzing TES gene expression profile in BC cells using the University of California Santa Cruz (UCSC) Xena browser database. Immunohistochemical analysis of TES protein was performed in BC tissue samples obtained from patients. It was found that d ‐mannose significantly inhibited the growth of MDA‐MB‐231 and MCF‐7 cells in a concentration and time‐dependent manner by activating the NF‐κB signaling pathway and upregulating TES expression. TES knockdown downregulated the NF‐κB1, NF‐κB2, and p65 protein expressions. Therefore, this study highlights that d ‐mannose have the potential to promote anticancer effects upon further trials using in vivo models and clinical studies.